Market access update
Market access update
Here’s our round up of healthcare market access news from Canada over recent months.
Coming into effect July 1, 2020 the new regulations are expected to:
The PMPRB is now re-drafting its guidelines in response to this change and undertaking a consultation.2
The news of the Canadian healthcare pricing reform follows several months of pricing and reimbursement developments, including:
The National Pharmacare plan conversation progresses with the June release of the final report of the Advisory Council on the Implementation of National Pharmacare.3
This reiterated the interim report’s three key recommendations underpinning the creation of a universal, single-payer public system:
The government will now consider the recommendations. We will monitor the developments and see if/how these recommendations are adopted following the federal elections in late 2019.
British Columbia (BC) announced in May it will seek to expand the use of biosimilars to allow spending on other therapies.4 BC PharmaCare patients will be required to switch to biosimilars from the reference products by late November.
“We know that our use rates can be much higher,”5 explained BC Minister of Health, Adrian Dix. “For example, the biosimilars for infliximab (known as Inflectra and Remsima) have a combined 5–10% use rate in Canada after four years on the market, compared with Norway (98%), United Kingdom (90%) and Scotland (85%). As a result, in 2017, Canada spent over $1.1 bn on the original biologic drug called Remicade.”
For the planned HTA re-assessment procedure, CADTH6 has outlined:
CADTH has noted that in the future, outcomes-based reimbursement agreements might also mandate reassessments
Digital transformation in market access
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.